Phage susceptibility testing methods or 'phagograms': where do we stand and where should we go?

被引:1
|
作者
Kolenda, Camille [1 ,2 ]
Jourdan, Julie [1 ]
Roussel-Gaillard, Tiphaine [1 ]
Medina, Mathieu [1 ,2 ]
Laurent, Frederic [1 ,2 ]
机构
[1] Hosp Civils Lyon, Inst Agents Infect, Serv bacteriol, Lyon, France
[2] Univ Claude Bernard Lyon 1, Univ Lyon, CIRI Ctr Int Rech Infectiol, Team StaPath,Inserm,U1111,CNRS,UMR5308,ENS Lyon, Lyon, France
关键词
BACTERIOPHAGE THERAPY; EFFICACY;
D O I
10.1093/jac/dkae325
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Phage therapy is a highly promising approach to address the challenge that is presented by the global burden of antimicrobial resistance. Given the natural specificity of phages, phage susceptibility testing (PST) is a prerequisite for successful personalized therapy, allowing the selection of active phages from large and diverse collections. However, the issue of an easy-to-use and standardized technique remains. In this review, we describe the principles, advantages and drawbacks of two routinely used PST techniques: plaque and growth kinetic assays. These are labour-intensive and time-consuming methods that require automation of one or more steps, including preparation of test panels, incubation, reading and analysis of results. In addition to automation, there is an urgent need to establish a reference method to enable efficient of PST techniques selection of therapeutic phages. We discuss knowledge gaps and parameters that need to be investigated to work towards this goal.
引用
收藏
页码:2742 / 2749
页数:8
相关论文
共 50 条
  • [31] Phage Therapy in the Resistance Era: Where Do We Stand and Where Are We Going?
    Luong, Tiffany
    Salabarria, Ann-Charlott
    Roach, Dwayne R.
    CLINICAL THERAPEUTICS, 2020, 42 (09) : 1659 - 1680
  • [32] Flow Chemistry & Catalysis - Where do we stand and where do we need to go?
    Vile, Gianvito
    CATALYSIS TODAY, 2018, 308 : 1 - 2
  • [33] High Energy Neutrino Astronomy: Where Do We Stand, Where Do We Go?
    Christian Spiering
    Physics of Particles and Nuclei, 2018, 49 : 497 - 507
  • [34] Special issue: Fuzzy sets: Where do we stand? Where do we go?
    Dubois, D
    Sandri, SA
    FUZZY SETS AND SYSTEMS, 1997, 90 (02) : 109 - 110
  • [35] Vascularization in skin wound healing: where do we stand and where do we go
    Moreira, Helena R.
    Marques, Alexandra P.
    CURRENT OPINION IN BIOTECHNOLOGY, 2022, 73 : 253 - 262
  • [36] Maximum entropy and Bayesian inference: Where do we stand and where do we go?
    Mohammad-Djafari, Ali
    BAYESIAN INFERENCE AND MAXIMUM ENTROPY METHODS IN SCIENCE AND ENGINEERING, 2006, 872 : 3 - 14
  • [37] Questions and answers in chronic urticaria: where do we stand and where do we go?
    Maurer, M.
    Church, M. K.
    Marsland, A. M.
    Sussman, G.
    Siebenhaar, F.
    Vestergaard, C.
    Broom, B.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 7 - 15
  • [38] Nutrition and the child with cancer: where do we stand and where do we need to go?
    Nieuwoudt, C. H.
    SOUTH AFRICAN JOURNAL OF CLINICAL NUTRITION, 2011, : S23 - S26
  • [39] Revisiting asthma pharmacotherapy: where do we stand and where do we want to go?
    Cazzola, Mario
    Page, Clive P.
    Matera, Maria Gabriella
    Rogliani, Paola
    Hanania, Nicola A.
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62 (02)
  • [40] Biologics in vasculitides: Where do we stand, where do we go from now?
    Pazzola, Giulia
    Muratore, Francesco
    Pipitone, Nicolo
    Salvarani, Carlo
    PRESSE MEDICALE, 2015, 44 (06): : E231 - E239